{'Year': '2023', 'Month': 'Jan'}
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug-drug interactions and adverse drug reactions, potentially avoidable in number and severity with the implementation of pharmacogenetic procedures. The accumulation of defective variants (>30 genes per patient in more than 50% of cases) in pharmagenes (pathogenic, mechanistic, metabolic, transporter, pleiotropic) influences the therapeutic response to antidementia, antidepressant and anxiolytic drugs in polyvalent regimens. <i>APOE</i>, <i>CYP1A2</i>, <i>CYP2C9</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>CYP2E1</i>, <i>CYP3A4</i>, <i>CYP3A5</i>, <i>CYP4F2</i>, <i>COMT</i>, <i>MAOB</i>, <i>CHAT</i>, <i>GSTP1</i>, <i>NAT2</i>, <i>SLC30A8</i>, <i>SLCO1B1</i>, <i>ADRA2A</i>, <i>ADRB2</i>, <i>BCHE</i>, <i>GABRA1</i>, <i>HMGCR</i>, <i>HTR2C</i>, <i>IFNL3</i>, <i>NBEA</i>, <i>UGT1A1</i>, <i>ABCB1</i>, <i>ABCC2</i>, <i>ABCG2</i>, <i>SLC6A2</i>, <i>SLC6A3</i>, <i>SLC6A4</i>, <i>MTHFR</i> and <i>OPRM1</i> variants affect anxiety and depression in Alzheimer's disease.